Amicus Therapeutics, Inc. 8-K Report: Key Insights for Investors on Feb 19, 2025

The extracted key information from the provided financial report section is as follows:

1. Entity Information:

• Company Name: Amicus Therapeutics, Inc.
• CIK: 0001178879
• State of Incorporation: Delaware (DE)
• SEC Central Index Key (CIK): 0001178879
• Address: 47 Hulfish Street, Princeton, NJ 08542
• Phone Number: 609-662-2000

2. Filing Details:

• Form Type: 8-K
• Filing Date: February 19, 2025
• SEC File Number: 001-33497
• Employer Identification Number (EIN): 71-0869350

3. Stock Information:

• Class of Stock: Common Stock
• Par Value: $0.01
• Ticker Symbol: FOLD
• Exchange: NASDAQ

4. Period Information:

• Report Date: February 19, 2025
• Context Period: The report is for a single day, with both the start and end date being February 19, 2025.

5. Units of Measurement:

• Currency: USD
• Shares: The report mentions shares, indicating that the financial data may relate to share price or share volume.

Insights:

• The filing is an 8-K, which typically indicates a significant event or corporate change, such as mergers, acquisitions, or other events that might impact the company's financial condition or operations.
• As Amicus Therapeutics is listed on NASDAQ under the ticker FOLD, this filing may be of interest to investors tracking the company's performance.
• The report is very recent as it pertains to a future date (February 19, 2025), suggesting it could be a forward-looking statement or announcement regarding anticipated corporate activities.

This information could be crucial for stakeholders, investors, and analysts monitoring the company's developments and performance in the pharmaceutical industry.